



PATENT  
ATTORNEY DOCKET NO. 50304/061001

Certificate of Mailing: Date of Deposit: December 21, 2006

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

J. Cooper McDonald  
Printed name of person mailing correspondence

J. Cooper McDonald  
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Balzarini et al. Art Unit: 1615  
Serial No.: 10/525,784 Examiner: Not Yet Assigned  
Filed: February 28, 2005 Customer No.: 21559  
Confirmation No.: 8526  
Title: GLYCOPEPTIDE ANTIBIOTIC DERIVATIVES

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed with the exception of U.S. patents and U.S. patent application publications. A copy of a search report from a corresponding international application is also enclosed.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.


This statement is being filed before the mailing of a first Office action on the merits.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date:

December 20, 2006



James D. DeCamp  
Reg. No. 43,580

Reg No 52,011

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045

Sheet 1 of 2

|   |   |  |                             |                                  |          |                                 |
|---|---|--|-----------------------------|----------------------------------|----------|---------------------------------|
| SUBSTITUTE FORM PTO-1449<br>(MODIFIED)  |   | U.S. DEPARTMENT OF COMMERCE<br>PATENT AND TRADEMARK OFFICE |                             | Attorney Docket No. 50304/061001 |          |                                 |
| INFORMATION DISCLOSURE<br>STATEMENT BY APPLICANT<br>(Use several sheets if necessary)   |   |  |                             | Serial No. 10/525,784            |          |                                 |
|   |   |  |                             | Applicant Balzarini et al.       |          |                                 |
|   |   |  |                             | Filing Date February 28, 2005    |          |                                 |
|   |   |  |                             | Group 1615                       |          |                                 |
|   |   |  |                             | IDS Filed December 21, 2006      |          |                                 |
| (37 C.F.R. §1.98(b))  |   |  |                             |                                  |          |                                 |
| U.S. PATENTS  |   |  |                             |                                  |          |                                 |
| Examiner's<br>Initials  | Patent Number   | Issue Date   | Patentee                    | Class                            | Subclass | Filing Date<br>(If Appropriate) |
|   | 5,500,410   | 03/19/96   | Malabarba et al.            |                                  |          |                                 |
|   | 5,521,155   | 05/28/96   | Malabarba et al.            |                                  |          |                                 |
| FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION  |   |  |                             |                                  |          |                                 |
| Examiner's<br>Initials  | Document<br>Number  | Publication<br>Date  | Country or<br>Patent Office | Class                            | Subclass | Translation<br>(Yes/No)         |
|   | 0,276,740 A1  | 08/03/88   | EPO                         |                                  |          |                                 |
|   | 0,365,319 A2  | 04/25/90   | EPO                         |                                  |          |                                 |
|   | 0,365,319 B1  | 08/23/95   | EPO                         |                                  |          |                                 |
|   | 0,667,353 A1  | 8/16/95  | EPO                         |                                  |          |                                 |
|   | 0,667,353 B1  | 08/16/95   | EPO                         |                                  |          |                                 |
|   | WO 00/69893 A1  | 11/23/00   | WIPO                        |                                  |          |                                 |
|   | WO 01/58933 A2  | 08/16/01   | WIPO                        |                                  |          |                                 |
|   | WO 01/81372 A2  | 11/01/01   | WIPO                        |                                  |          |                                 |
| OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)   |   |  |                             |                                  |          |                                 |
|   | Allen et al., "Hexapeptide Derivatives of Glycopeptide Antibiotics: Tools for Mechanism of Action Studies," <i>Antimicrob. Agents and Chemother.</i> 46:2344-2348 (2002).   |  |                             |                                  |          |                                 |
|   | Borghi et al., "Microbial De-Mannosylation and Mannosylation of Teicoplanin Derivatives," <i>J. Antibiot. (Tokyo)</i> 44:1444-1451 (1991).  |  |                             |                                  |          |                                 |
|   | Georgiou et al., "The Chemotherapeutic Agent Bleomycin in a Two-Drug Combination with Zidovudine, Ritonavir or Indinavir Synergistically Inhibits HIV Type-1 Replication in Peripheral Blood Lymphocytes," <i>Int. J. Antimicrob. Agents</i> , 18:513-518 (2001). |  |                             |                                  |          |                                 |
| EXAMINER  |   |  | DATE CONSIDERED             |                                  |          |                                 |
| EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant. |   |  |                             |                                  |          |                                 |

